Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma.
Saito
B
B
Shiozawa
E
E
Usui
T
T
Nakashima
H
H
Maeda
T
T
Hattori
N
N
Shimozuma
J
J
Adachi
D
D
Yamochi-Onizuka
T
T
Takimoto
M
M
Nakamaki
T
T
Ota
H
H
Tomoyasu
S
S
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004341:Drug Evaluation; D005260:Female; D019254:Genes, bcl-2; D006801:Humans; D007167:Immunotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D011239:Prednisolone / Q000008:administration & dosage; D012189:Retrospective Studies; D000069283:Rituximab; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D016328:NF-kappa B; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; C027260:pirarubicin